{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-029096","form_type":"8-K","ticker":"VTGN","cik":"0001411685","company_name":"Vistagen Therapeutics, Inc.","filed_at":"2023-10-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.970818+00:00","generated_at":"2026-06-09T08:19:16.429524+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Joshua Prince appointed COO of Vistagen Therapeutics","bullets":["Joshua Prince appointed Chief Operating Officer effective Oct 24, 2023; had been SVP Business Operations since Nov 2021.","Prince brings over 20 years pharma experience including roles at CSL Behring, Teva, and AstraZeneca.","Holds a BS in Mechanical Engineering from Missouri-Rolla and an MBA from Penn State.","Company entered into standard Indemnification Agreement with Prince for his service."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-029096","json":"https://secwatch.observer/filing/0001437749-23-029096.json","markdown":"https://secwatch.observer/filing/0001437749-23-029096.md","text":"https://secwatch.observer/filing/0001437749-23-029096.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411685/000143774923029096/0001437749-23-029096-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411685/000143774923029096/vtgn20231026_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T08:19:16.429524+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e97554eb8e","claim":"Joshua Prince was appointed as Chief Operating Officer at Vistagen Therapeutics, Inc..","evidence_excerpt":"On October 24, 2023, Joshua Prince was appointed to serve as the Chief Operating Officer of Vistagen Therapeutics, Inc. (the “ Company ”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1411685/000143774923029096/0001437749-23-029096-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}